AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2561597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrophosphate/copolymer toothpaste
Number of subjects: 50
Study 2561597 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 50
Study 1147500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam preoperatively
Number of subjects: 0
Study 1147500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31743136 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2 to 3 mg/kg)
Number of subjects: 98
Study 31743136 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.2 to 0.3 mg/kg)
Number of subjects: 98
Study 31285490 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Group Training (SSGT)
Number of subjects: 207
Study 31285490 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 207
Study 26500228 — intervention group
Group type: EXPERIMENTAL
Intervention: Home detention
Number of subjects: 0
Study 26500228 — intervention group
Group type: EXPERIMENTAL
Intervention: Early work release
Number of subjects: 0
Study 26500228 — intervention group
Group type: COMPARATOR
Intervention: Custody (Control Group)
Number of subjects: 0
Study 26264550 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus DASH-based dietary counselling (n = 281)
Number of subjects: 556
Study 26264550 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard education, control) (n = 275)
Number of subjects: 556
Study 24060106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program
Number of subjects: 160
Study 24060106 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (bi-monthly telephone contact)
Number of subjects: 160
Study 20820791 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meal replacement diet containing a vegetable-oil emulsion
Number of subjects: 0
Study 20820791 — intervention group
Group type: COMPARATOR
Intervention: Dairy fat (control)
Number of subjects: 0
Study 19245687 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 455
Study 19245687 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 455
Study 19245687 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 455
Study 17711691 — intervention group
Group type: EXPERIMENTAL
Intervention: Diver CE device
Number of subjects: 122
Study 17711691 — intervention group
Group type: COMPARATOR
Intervention: Guardwire Plus device
Number of subjects: 122
Study 15316094 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 0.75 mg/day
Number of subjects: 54
Study 15316094 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 2.5 mg/day
Number of subjects: 54
Study 15316094 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day
Number of subjects: 54
Study 15316094 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day
Number of subjects: 54
Study 15316094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 11246591 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study 11246591 — intervention group
Group type: COMPARATOR
Intervention: Multivitamins containing folic acid
Number of subjects: 0
Study 9109044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirilazad mesylate 10.0 mg/kg/day for 5 days
Number of subjects: 55
Study 9109044 — intervention group
Group type: EXPERIMENTAL
Intervention: U-89678 (active metabolite)
Number of subjects: 55
Study 8110306 — intervention group
Group type: COMPARATOR
Intervention: Single-breast feeding
Number of subjects: 80
Study 8110306 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-breast feeding
Number of subjects: 80
Study 3539631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol (90 mg orally for 14 days)
Number of subjects: 11
Study 3539631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 14 days)
Number of subjects: 11
Study 29692607 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Number of subjects: 0
Study 27184046 — intervention group
Group type: EXPERIMENTAL
Intervention: Anbainuo (etanercept)
Number of subjects: 600
Study 24525630 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral suprazygomatic maxillary nerve block with 0.15 ml/kg of 0.2% ropivacaine
Number of subjects: 60
Study 24525630 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 60
Study 22632908 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 3035
Study 22632908 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3035
Study 20710058 — intervention group
Group type: EXPERIMENTAL
Intervention: JTK-652 (100 mg three times daily for 4 weeks)
Number of subjects: 10
Study 20710058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20710058 — intervention group
Group type: EXPERIMENTAL
Intervention: JTK-652
Number of subjects: 10
Study 17050021 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery rehearsal in addition to normal physical therapy (12 individual sessions)
Number of subjects: 20
Study 17050021 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only
Number of subjects: 20
Study 16264002 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicaid
Number of subjects: 401
Study 16264002 — intervention group
Group type: COMPARATOR
Intervention: Private Insurance
Number of subjects: 401
Study 16264002 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinics accepting Medicaid
Number of subjects: 401
Study 16264002 — intervention group
Group type: COMPARATOR
Intervention: Clinics not accepting Medicaid
Number of subjects: 401
Study 16264002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-poverty clinics
Number of subjects: 401
Study 16264002 — intervention group
Group type: COMPARATOR
Intervention: Non-high-poverty clinics
Number of subjects: 401
Study 11904107 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (1 g/d, n = 111)
Number of subjects: 223
Study 11904107 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 112)
Number of subjects: 223
Study 10447535 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) at 80% compensation (PAV(80))
Number of subjects: 13
Study 10447535 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV) at 50% compensation (PAV(50))
Number of subjects: 13
Study 10447535 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 13
Study 8706195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms x kg(‐1)
Number of subjects: 60
Study 8706195 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms x kg(‐1)
Number of subjects: 60
Study 8706195 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0.4 x kg(‐1) (active control)
Number of subjects: 60
Study 1455195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Cyclosporin
Number of subjects: 12
Study 1455195 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of Cyclosporin
Number of subjects: 12
Study 4014186 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewer-administered questionnaire
Number of subjects: 0
Study 4014186 — intervention group
Group type: COMPARATOR
Intervention: Self-administered questionnaire
Number of subjects: 0
Study 4014186 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical variables
Number of subjects: 0
Study 4014186 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet histories
Number of subjects: 0
Study 30829137 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU weekly for 16 weeks)
Number of subjects: 46
Study 30829137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29986492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 343
Study 29986492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified corn-soy blend (CSB+) with iron and folic acid (CSB+IFA)
Number of subjects: 343
Study 29986492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified corn-soy blend (CSB+) with multiple-micronutrient supplement (CSB+UNIMMAP)
Number of subjects: 343
Study 26908432 — intervention group
Group type: EXPERIMENTAL
Intervention: Mainly exercise
Number of subjects: 243
Study 26908432 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 243
Study 26908432 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 243
Study 25559753 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate and carbohydrate (WPH+CHO)
Number of subjects: 24
Study 25559753 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate (CHO)
Number of subjects: 24
Study 25559753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WPH+CHO and CHO
Number of subjects: 24
Study 23802706 — intervention group
Group type: EXPERIMENTAL
Intervention: Q8003 (morphine/oxycodone combination) 12 mg/8 mg
Number of subjects: 522
Study 23802706 — intervention group
Group type: COMPARATOR
Intervention: morphine 12 mg
Number of subjects: 522
Study 23802706 — intervention group
Group type: COMPARATOR
Intervention: oxycodone 8 mg
Number of subjects: 522
Study 20226390 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (mean dose, 528 IU/d)
Number of subjects: 42
Study 20226390 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight or vitamin D supplementation
Number of subjects: 42
Study 20226390 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D plus calcium therapy (from Women's Health Initiative Randomized Trial)
Number of subjects: 42
Study 19138241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (100 mg, single dose)
Number of subjects: 30
Study 19138241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 16670444 — intervention group
Group type: EXPERIMENTAL
Intervention: PicoElite stent (PES group)
Number of subjects: 30
Study 16670444 — intervention group
Group type: COMPARATOR
Intervention: bare metal ArthosPico stent (BMS group)
Number of subjects: 30
Study 12833111 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) for 9 weeks
Number of subjects: 27
Study 12833111 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance for one year after VLCD
Number of subjects: 27
Study 12833111 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD)
Number of subjects: 27
Study 12833111 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance after VLCD
Number of subjects: 27
Study 10843168 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 19
Study 10843168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10843168 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy after placebo
Number of subjects: 19
Study 7702136 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 3 mg in bolus with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Number of subjects: 54
Study 7702136 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 3 mg in infusion with bupivacaine 10 ml of 0.25% followed by infusion of bupivacaine 0.1% at 10 ml.h‐1
Number of subjects: 54
Study 2693684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% chlorhexidine rinse
Number of subjects: 9
Study 2693684 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 9
Study 678393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 6.25 mg
Number of subjects: 24
Study 678393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 12.5 mg
Number of subjects: 24
Study 678393 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 24
Study 678393 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline 25 mg
Number of subjects: 24
Study 678393 — intervention group
Group type: COMPARATOR
Intervention: Protriptyline 10 mg
Number of subjects: 24
Study 678393 — intervention group
Group type: COMPARATOR
Intervention: BW247 12.5 mg
Number of subjects: 24
Study 678393 — intervention group
Group type: COMPARATOR
Intervention: BW247 25 mg
Number of subjects: 24
Study 31475493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Number of subjects: 70
Study 31475493 — intervention group
Group type: COMPARATOR
Intervention: Medication (Mannitol Injection 125 mL every 8 hours, Oxiracetam Injection 4 g once a day)
Number of subjects: 70
Study 31475493 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus medication
Number of subjects: 70
Study 31475493 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 70
Study 28682897 — intervention group
Group type: COMPARATOR
Intervention: Difficult laryngoscopy (DL)
Number of subjects: 24
Study 28682897 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy laryngoscopy (EL)
Number of subjects: 24
Study 26152604 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose dabigatran (110mg bid)
Number of subjects: 149
Study 26152604 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted acenocoumarol
Number of subjects: 149
Study 23062064 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 40
Study 23062064 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 40
Study 23062064 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc
Number of subjects: 40
Study 23062064 — intervention group
Group type: COMPARATOR
Intervention: Intact control group (negative control)
Number of subjects: 40
Study 21641951 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 A
Number of subjects: 1114
Study 21641951 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 B
Number of subjects: 1114
Study 21641951 — intervention group
Group type: COMPARATOR
Intervention: tOPV X
Number of subjects: 1114
Study 21641951 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 C
Number of subjects: 1114
Study 21641951 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 D
Number of subjects: 1114
Study 21641951 — intervention group
Group type: COMPARATOR
Intervention: tOPV Y
Number of subjects: 1114
Study 18580126 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical methods of antipyresis (e.g., cooling blankets)
Number of subjects: 0
Study 18580126 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling methods
Number of subjects: 0
Study 16931415 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program including pain policy and educational program for healthcare professionals
Number of subjects: 0
Study 16931415 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program
Number of subjects: 0
Study 16931415 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 12680909 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion (8 pmol (kg min)(-1) for 5 min)
Number of subjects: 8
Study 12680909 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 12680909 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion following an antral phase III
Number of subjects: 8
Study 12680909 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 8
Study 10878624 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflow stent
Number of subjects: 1147
Study 10878624 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI‐LINK stent
Number of subjects: 1147
Study 10878624 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR stent
Number of subjects: 1147
Study 10878624 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz stent
Number of subjects: 1147
Study 10878624 — intervention group
Group type: EXPERIMENTAL
Intervention: PURA‐A stent
Number of subjects: 1147
Study 10878624 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1147
Study 9436666 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 0
Study 9436666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8421029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dose of cephamandole at the time of tourniquet deflation
Number of subjects: 32
Study 8421029 — intervention group
Group type: COMPARATOR
Intervention: Serum concentration of cephamandole
Number of subjects: 32
Study 3534590 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus 12 cycles of cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF)
Number of subjects: 0
Study 3534590 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 3534590 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of CMF
Number of subjects: 0
Study 3534590 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose sequential non-cross-resistant combinations
Number of subjects: 0
Study 3534590 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF
Number of subjects: 0
Study 3534590 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative activity (labeling index) of the primary tumor
Number of subjects: 0
Study 29877872 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression alone
Number of subjects: 85
Study 29877872 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression plus fusion
Number of subjects: 85
Study 29877872 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression plus stabilization
Number of subjects: 85
Study 26845175 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1.2 mg/m2 administered over 24 h on day 1 of a 21-d treatment cycle)
Number of subjects: 30
Study 26845175 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 30
Study 26845175 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 30
Study 24020826 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free timolol gel
Number of subjects: 40
Study 24020826 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved timolol eye drops
Number of subjects: 40
Study 24020826 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 40
Study 23198943 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum-chewing group (n=50)
Number of subjects: 100
Study 23198943 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=50)
Number of subjects: 100
Study 20836304 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival Autograft Technique (CAG)
Number of subjects: 122
Study 20836304 — intervention group
Group type: COMPARATOR
Intervention: Minimally Invasive Pterygium Surgery (MIPS)
Number of subjects: 122
Study 18215610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleeding events (no bleeding, mild bleeding, moderate bleeding, severe bleeding)
Number of subjects: 1235
Study 18215610 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe bleeding events
Number of subjects: 1235
Study 18215610 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion events
Number of subjects: 1235
Study 18215610 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay
Number of subjects: 1235
Study 15825917 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal lobe dementia patients
Number of subjects: 80
Study 15825917 — intervention group
Group type: COMPARATOR
Intervention: Subcortical vascular dementia patients
Number of subjects: 80
Study 12860778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride, mean dosage of 95 mg/d
Number of subjects: 44
Study 12860778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 12860778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 44
Study 10668525 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (20 mg/day after a loading dose of 100 mg/day for 3 days)
Number of subjects: 0
Study 10668525 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5‐15 mg/week)
Number of subjects: 0
Study 10668525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in US301)
Number of subjects: 0
Study 8561065 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 high-fish diet (n = 11)
Number of subjects: 22
Study 8561065 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 2 low-fish diet (n = 11)
Number of subjects: 22
Study 8561065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Step 2 diets
Number of subjects: 22
Study 1991872 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine varnish
Number of subjects: 44
Study 1991872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 44
Study 1991872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 44
Study 6426992 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate 100 mg orally
Number of subjects: 12
Study 6426992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30326747 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning Walk® group (n=28)
Number of subjects: 58
Study 30326747 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 58
Study 30298808 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge, attitudes, and practices (KAP) questionnaire
Number of subjects: 505
Study 25955771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 40
Study 25955771 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 40
Study 25026953 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient technique
Number of subjects: 223
Study 25026953 — intervention group
Group type: COMPARATOR
Intervention: Swim up technique
Number of subjects: 223
Study 22677537 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 M sucrose (sweet) alone and mixed with barium
Number of subjects: 80